MET-PE — MetLife, Inc.

MetLife Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings: $1.6 billion, or $2.34 per share (up 21% year-over-year), with notable items totaling $18 million or $0.03 per share.
• Variable Investment Income: $483 million, exceeding the $425 million guidance, driven by strong private equity returns (3% for the quarter).
• Adjusted Return on Equity: 16.7%, aligning with the target range of 15% to 17%.
• Direct Expense Ratio: 11.6%, below the full-year target of 12.1%.
• Shareholder Returns: Approximately $875 million returned through dividends and share repurchases in Q3, with year-to-date buybacks totaling $2.6 billion.

2. Strategic Updates and Business Highlights

• New Frontier Strategy: The strategy is showing positive results, particularly in Group Benefits, Retirement, and Asia.
• Group Benefits: Adjusted earnings of $457 million (up 6%), driven by improved underwriting results and seasonal profitability in dental.
• Retirement and Income Solutions (RIS): Adjusted earnings of $423 million (up 15%), with strong growth in structured settlements and U.K. longevity reinsurance.
• Asia Performance: Adjusted earnings of $473 million (up 36%), with sales growth of 34% on a constant currency basis, particularly strong in Japan (31% increase).
• Latin America: Adjusted earnings of $222 million (up 2%), with continued business momentum and partnerships, such as with MercadoLibre.
• Chariot Re Launch: A new reinsurance initiative aimed at enhancing retirement liability origination capacity.

3. Forward Guidance and Outlook

• Pension Risk Transfer (PRT): Anticipated to be a record quarter with $12 billion already written in Q4, indicating strong market trust.
• Expense Management: Expected to remain below the 12.1% target for the full year, aided by technology investments and operational efficiencies.
• Long-term Growth: Positive outlook for PRT business with 94% of pension plan sponsors planning to derisk portfolios in the next five years.

4. Bad News, Challenges, or Points of Concern

• Tax Law Changes in Mexico: A notable charge of $71 million related to VAT deductions affecting health insurance claims, expected to impact earnings by $50-$60 million in 2026.
• Group Benefits Underwriting: The group life mortality ratio was below target at 83.3%, raising concerns about future profitability.
• Market Competition: The competitive environment remains rational but poses ongoing challenges for pricing and growth in Group Benefits.

5. Notable Q&A Insights

• Asia Sales Momentum: Continued strong performance attributed to new product launches and enhancements, with expectations to exceed full-year sales guidance.
• PRT Competitive Landscape: Emphasis on MetLife's strengths in the jumbo market, highlighting financial strength and disciplined risk management as key competitive advantages.
• Expense Seasonality: Anticipated higher expenses in Q4 but still below the full-year target, with technology investments contributing to efficiency gains.
• Long-Term Care (LTC) Market: MetLife remains disciplined in exploring risk transfer opportunities while maintaining a well-capitalized and managed book of business.

Overall, MetLife's Q3 2025 results reflect strong financial performance, strategic growth initiatives, and a positive outlook, tempered by some challenges in specific markets and regulatory environments.